Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Long-term survival in a patient with BRCA2-mutated pleomorphic anaplastic pancreatic carcinoma treated with Olaparib maintenance therapy.

Clinical journal of gastroenterology - 1 Apr 2026

Kubota Jun, Masuda Sakue, Makazu Makomo, Kimura Karen, Imaeda Shunsuke, Teshima Shinichi, Wada Keitaro, Koizumi Kazuya

Abstract excerpt

Anaplastic pancreatic carcinoma (APC) is an extremely rare and aggressive histological subtype of pancreatic cancer with a poor prognosis. The therapeutic significance of BRCA1/2 mutations, which are established targets in pancreatic ductal adenocarcinoma (PDAC), remains unclear in APC. We report the case of a man in his 70s diagnosed with metastatic pleomorphic APC. Germline testing revealed a pathogenic BRCA2...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA2 Protein
Share to Carcinoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fluorouracil

Share to Genes, BRCA2

Share to Maintenance Chemotherapy

Share to Phthalazines

Share to Piperazines

Share to Poly(ADP-ribose) Polymerase Inhibitors

Source

Identifiers

PMID: 41691559
DOI: 10.1007/s12328-026-02285-5

Genes

APC
BRCA2
BRCA1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Long-term survival in a patient with BRCA2-mutated pleomorphic anaplastic pancreatic carcinoma treated with Olaparib maintenance therapy.PMID 41691559Read ↗

Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic CancerSemantic proximity Read ↗

Olaparib as a single agent treatment in pre-treated metastatic pancreatic cancer patient harboring BRCA2 mutation: What could we expect?Semantic proximity Read ↗

Unusual metastasis in BRCA mutated pancreatic cancer while on maintenance Olaparib: Two case reports and review of the literature.Semantic proximity Read ↗

Olaparib Monotherapy for Previously Treated Pancreatic Cancer With DNA Damage Repair Genetic Alterations Other Than Germline BRCA VariantsSemantic proximity Read ↗

An evaluation of olaparib for the treatment of pancreatic cancer.Semantic proximity Read ↗

The role of PARP inhibitors in BRCA mutated pancreatic cancerSemantic proximity Read ↗

Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic CancerSemantic proximity Read ↗

Durable response to olaparib in pancreatic duct adenocarcinoma with deleterious ARID1A mutation.Semantic proximity Read ↗

Exceptional Response to Olaparib and Pembrolizumab for Pancreatic Adenocarcinoma With Germline BRCA1 Mutation and High Tumor Mutation Burden: Case Report and Literature Review.Semantic proximity Read ↗

Poly( ADP ‐ribose) polymerase inhibition in pancreatic cancerSemantic proximity Read ↗

Long-term complete remission of two patients with synchronous liver metastasis from pancreatic cancer and underlying BRCA-2 mutation.Semantic proximity Read ↗

A case of BRCA1-mutated giant pancreatic acinar cell carcinoma successfully treated with modified FOLFIRINOX therapy and radical resection.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.